Revium Rx S-1 registration statements

Revium Rx filed an exhibits-only Amendment No. 5 to its S-1 Registration Statement, detailing corporate governance changes and director compensation arrangements.

Revium Rx filed an S-1/A for a self-underwritten public offering of 1.56 million units and a resale of up to 37.6 million common shares by existing stockholders, focusing on lipid-based therapies for antibiotic resistance and cancer.

Revium Rx, a preclinical biotech firm, is launching a self-underwritten IPO to fund its lipid-based therapies, while facing delays in its lead drug candidates and a dispute over a critical license option.

Pre-clinical biotech Revium Rx files an S-1/A for a self-underwritten initial public offering to fund its lipid-based therapies for antibiotic resistance and cancer, despite a history of significant losses.

Revium Rx., a preclinical biotechnology company, filed an S-1/A for a self-underwritten public offering to fund its advanced lipid-based therapies for antimicrobial resistance and solid tumors.

Revium Rx, formerly OC Beverages, files an S-1 registration statement for an initial public offering of units and resale of common stock by selling stockholders.